| scholarly article | Q13442814 |
| P2093 | author name string | C. K. van der Ent | |
| A. M M. de Vrankrijker | |||
| T. F W. Wolfs | |||
| P2860 | cites work | Prospective evaluation of emerging bacteria in cystic fibrosis | Q81488171 |
| Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients | Q81898474 | ||
| Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis | Q24240074 | ||
| Vaccines for preventing influenza in people with cystic fibrosis | Q24240244 | ||
| The effect of respiratory viral infections on patients with cystic fibrosis | Q69350172 | ||
| Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? | Q73445073 | ||
| Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp | Q73471944 | ||
| Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia | Q73675033 | ||
| Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis | Q73912840 | ||
| Respiratory viral infections in adults with and without chronic obstructive pulmonary disease | Q74025605 | ||
| Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis | Q74525867 | ||
| Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence | Q74683395 | ||
| Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol | Q79441115 | ||
| Proposal of Burkholderia gen. nov. and Transfer of Seven Species of the Genus Pseudomonas Homology Group II to the New Genus, with the Type Species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov | Q28184131 | ||
| Microbiology of early CF lung disease | Q28246451 | ||
| Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis | Q28346183 | ||
| Predictive 5-year survivorship model of cystic fibrosis | Q30481059 | ||
| Nontuberculous mycobacteria in the environment | Q30737099 | ||
| Burkholderia and emerging pathogens in cystic fibrosis | Q30998871 | ||
| Burkholderia cepacia epidemiology and pathogenesis: implications for infection control. | Q33920031 | ||
| Taxonomy and identification of the Burkholderia cepacia complex | Q33973532 | ||
| Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis | Q34058533 | ||
| CFTR mutations and host susceptibility to Pseudomonas aeruginosa lung infection. | Q34521841 | ||
| Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis | Q34686580 | ||
| Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. | Q34732912 | ||
| Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis | Q34765872 | ||
| Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis | Q34796605 | ||
| Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis | Q35005445 | ||
| Non-tuberculous mycobacteria in cystic fibrosis | Q35532270 | ||
| Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. | Q35534898 | ||
| Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study | Q35535433 | ||
| Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. | Q35536357 | ||
| Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis | Q35557791 | ||
| Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients | Q35573139 | ||
| Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients | Q35784162 | ||
| Phenotypic characterization of clonal and nonclonal Pseudomonas aeruginosa strains isolated from lungs of adults with cystic fibrosis | Q35913962 | ||
| Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak | Q36572695 | ||
| An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases | Q36727850 | ||
| Community study of role of viral infections in exacerbations of asthma in 9-11 year old children | Q36903511 | ||
| Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel | Q36944748 | ||
| Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998. | Q37074730 | ||
| Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis | Q37334924 | ||
| Pseudomonas aeruginosa genotype prevalence in Dutch cystic fibrosis patients and age dependency of colonization by various P. aeruginosa sequence types. | Q37451717 | ||
| Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa | Q37909036 | ||
| Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. | Q39972823 | ||
| Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium | Q40013162 | ||
| RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells | Q40130043 | ||
| Nonrespiratory Stenotrophomonas maltophilia infection at a children's hospital | Q40611559 | ||
| Pseudomonas cepacia infection in cystic fibrosis: an emerging problem | Q40829590 | ||
| Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. | Q41091925 | ||
| Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark | Q41145157 | ||
| Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis | Q42128697 | ||
| A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. | Q42604401 | ||
| Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units | Q42632850 | ||
| Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors | Q43541393 | ||
| In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations | Q43785359 | ||
| Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre | Q43819799 | ||
| Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function | Q43952910 | ||
| An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre | Q44021808 | ||
| Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients | Q44063120 | ||
| Nontuberculous Mycobacteria in Adult Patients with Cystic Fibrosis | Q44146527 | ||
| Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis | Q44248035 | ||
| Respiratory syncytial virus infection facilitates acute colonization of Pseudomonas aeruginosa in mice. | Q44455329 | ||
| Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. | Q44528304 | ||
| Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol. | Q44544435 | ||
| Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. | Q44788277 | ||
| Microbiology of sputum from patients at cystic fibrosis centers in the United States | Q44982403 | ||
| Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis | Q45119582 | ||
| Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis | Q45395565 | ||
| Respiratory syncytial virus infection in a murine model of cystic fibrosis | Q45418609 | ||
| Impaired Innate Host Defense Causes Susceptibility to Respiratory Virus Infections in Cystic Fibrosis | Q45723562 | ||
| Mycobacterium abscessus from respiratory isolates: activities of drug combinations. | Q46091385 | ||
| Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis | Q46453243 | ||
| Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. | Q47249113 | ||
| Role of CFTR in airway disease | Q47606626 | ||
| Early rise of anti-pseudomonas antibodies and a mucoid phenotype of pseudomonas aeruginosa are risk factors for development of chronic lung infection--a case control study | Q47655756 | ||
| Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis | Q47793000 | ||
| Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. | Q47849237 | ||
| Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. | Q47855663 | ||
| Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales | Q50146857 | ||
| Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. | Q50585940 | ||
| Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. | Q50710550 | ||
| Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study. | Q51140673 | ||
| Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. | Q51697432 | ||
| Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. | Q51702025 | ||
| Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. | Q51702027 | ||
| Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. | Q51708622 | ||
| Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. | Q53359169 | ||
| Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. | Q53996192 | ||
| Bacterial colonisation with Xanthomonas maltophilia--a retrospective study in a cystic fibrosis patient population. | Q54200267 | ||
| Rapid screening of methicillin-resistant Staphylococcus aureus using PCR and chromogenic agar: a prospective study to evaluate costs and effects. | Q54437707 | ||
| Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study. | Q54505119 | ||
| Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients | Q59139155 | ||
| Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment | Q59139173 | ||
| Epidemiology Of Chronic Pseudomonas aeruginosa Infections In Cystic Fibrosis | Q59334968 | ||
| Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients | Q64134536 | ||
| Prevalence and significance of methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis | Q68094118 | ||
| Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients | Q68709409 | ||
| Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections | Q68876091 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| emerging pathogen | Q108429945 | ||
| P304 | page(s) | 246-254 | |
| P577 | publication date | 2010-08-07 | |
| P1433 | published in | Paediatric Respiratory Reviews | Q15759971 |
| P1476 | title | Challenging and emerging pathogens in cystic fibrosis | |
| P478 | volume | 11 |
| Q35106217 | AmgRS-mediated envelope stress-inducible expression of the mexXY multidrug efflux operon of Pseudomonas aeruginosa |
| Q39474102 | Antimicrobial and antibiofilm activity of secondary metabolites of lichens against methicillin-resistant Staphylococcus aureus strains from cystic fibrosis patients |
| Q38340865 | Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis--where do we stand? |
| Q40287629 | Burkholderia cepacia septicemia in a pediatric oncology patient: a pharmacotherapy challenge |
| Q42249988 | Clonally related Burkholderia contaminans among ventilated patients without cystic fibrosis |
| Q28077411 | Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms |
| Q46243765 | Direct detection of Exophiala and Scedosporium species in sputa of patients with cystic fibrosis |
| Q28541755 | Effects of green tea compound epigallocatechin-3-gallate against Stenotrophomonas maltophilia infection and biofilm |
| Q39074001 | Exposure to extremely low-frequency magnetic field affects biofilm formation by cystic fibrosis pathogens. |
| Q58817590 | Fungi in Cystic Fibrosis: Recent Findings and Unresolved Questions |
| Q36324439 | Identification and analysis of genomic islands in Burkholderia cenocepacia AU 1054 with emphasis on pathogenicity islands. |
| Q34539806 | Identification of Pseudomonas aeruginosa phenazines that kill Caenorhabditis elegans |
| Q31085356 | Insights into the evolution of sorbitol metabolism: phylogenetic analysis of SDR196C family |
| Q41756431 | Interaction between atypical microorganisms and E. coli in catheter-associated urinary tract biofilms |
| Q34351419 | Microbial communities in the upper respiratory tract of patients with asthma and chronic obstructive pulmonary disease |
| Q48234771 | Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients. |
| Q34348146 | Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. |
| Q36933502 | Potentiation of Aminoglycoside Activity in Pseudomonas aeruginosa by Targeting the AmgRS Envelope Stress-Responsive Two-Component System |
| Q37961906 | Providing β-lactams a helping hand: targeting the AmpC β-lactamase induction pathway. |
| Q38101836 | Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review |
| Q35151823 | Rapid detection and immune characterization of Mycobacterium abscessus infection in cystic fibrosis patients |
| Q40064693 | Structural/mechanistic insights into the efficacy of non-classical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates. |
| Q35987112 | The lung tissue microbiome in chronic obstructive pulmonary disease |
Search more.